Antagonists of MCP proteins

Drug – bio-affecting and body treating compositions – Lymphokine

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S324000, C536S023500, C435S069500, C435S071100, C435S325000, C435S252300, C435S320100

Reexamination Certificate

active

10510658

ABSTRACT:
Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.

REFERENCES:
patent: 5094941 (1992-03-01), Hart
patent: 5116964 (1992-05-01), Capon et al.
Hemmerich et al (1999), Biochemistry, 38, pp. 13013-13025.
Mikayama et al. Proc. Natl. Acad. Sci. USA vol. 90, pp. 10056-10060.
Voet et al. Biochemistry John Wiley & Sons, Inc., pp. 126-128 and 228-234.
Eck & Wilson in Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill New York, 1996.
Hemmerich, S. et al. “Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2”,Biochemistry, Oct. 5, 1999, pp. 13013-13025, vol. 38, No. 40.
Steitz, S. A. et al. “Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis”,FEBS Letters, Jul. 3, 1998, pp. 158-164, vol. 430, No. 3.
Seet, B. T. et al. “Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor”,Proceedings of the National Academy of Sciences of the United States, Jul. 31, 2001, pp. 9008-9013, vol. 98, No, 16.
Mayer, M. R. et al. “Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin”,Journal of Biological Chemistry, Apr. 27, 2001, pp. 13911-13916, vol. 276, No. 17.
Chakravarty, L. et al. “Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding”,Journal of Biological Chemistry, Nov. 6, 1998, pp. 29641-29647, vol. 273, No. 45.
Dawson, J. et al. “Targeting monocyte chemoattractant protein-1 signaling in disease”,Expert Opinion on Therapeutic Targets, Feb. 2003, pp. 35-48, vol. 7, No. 1.
Proudfoot, A. E. I. et al. “Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines”,PNAS, Feb. 18, 2003, pp. 1885-1890, vol. 100, No. 4.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antagonists of MCP proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonists of MCP proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of MCP proteins will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3949768

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.